02/27/2008
TyRx Pharma, Inc. Raises $25 Million in Private Financing
Proceeds Will Support Commercialization of the AIGISrx™ CRMD Anti-Bacterial Envelope and Development Launch of Additional Dreg-Eluting Devices in the TyRx Pipeline
Cooley Godward Kronish represented TyRx Pharma, Inc. in its Series E Preferred Stock Financing. Team members included partners John Hession and Marc Recht, and associate Luke Albrecht.
Monmouth Junction, NJ, (February 27, 2008) – TyRx Pharma, Inc., a leader in the commercialization of implantable combination drug-device products, announced today that the Company has raised $25 million in a venture capital financing led by Clarus Ventures and co-led by Pappas Ventures. In connection with the financing, Jeffrey Leiden, M.D., Ph.D., Managing Director, and Scott Requadt, J.D., MBA, Principal, both of Clarus Ventures, and Arthur Pappas, Managing Partner, Pappas Ventures, will join TyRx's Board of Directors.
To read the full press release, click here.